Boston Scientific Corporation (BSX) recently received the Food and Drug Administration’s (FDA) approval to expand the indication for current-generation INGEVITY+ Pacing Leads. Expanded indication for INGEVITY+ Pacing Leads means thin wires will be placed inside the heart that will be connected to an implantable device. It can be used to include conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) when connected to a single or dual-chamber pacemaker.The latest FDA approval enhance ...

Boston Scientific (BSX) closed the most recent trading day at $82.52, moving -1.19% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.03%. Meanwhile, the Dow lost 0.04%, and the Nasdaq, a tech-heavy index, added 0.2%.The the stock of medical device manufacturer has risen by 6.14% in the past month, leading the Medical sector's gain of 2.67% and the S&P 500's gain of 1.54%.Analysts and investors alike will be keeping a close eye on the performance of Boston ...

Core Viewpoint - Boston Scientific is experiencing significant investor interest as its shares reach all-time highs, driven by a strong portfolio of medical devices and favorable market conditions related to an aging population and chronic diseases [1]. Group 1: Company Overview - Boston Scientific is a global medical device manufacturer with a diverse range of products aimed at diagnosing and treating various medical conditions [1]. - The company has announced the acquisition of Silk Road Medical for $1.1 billion, which is expected to close by the end of the year [2]. - Boston Scientific operates primarily in two segments: MedSurg and Cardiovascular, with MedSurg generating 36% of total revenue and Cardiovascular generating 64% [3][4]. Group 2: Financial Performance - In Q2 2024, Boston Scientific reported EPS of 62 cents, exceeding analyst estimates, and revenues rose 14.5% year-over-year to $4.12 billion [5]. - The company expects net sales for Q3 2024 to grow 13% to 15% year-over-year, with adjusted EPS projected between 57 cents and 59 cents [7]. - For the full year 2024, Boston Scientific anticipates revenues to grow between $16.162 billion and $16.305 billion, surpassing consensus estimates [7]. Group 3: Segment Performance - The MedSurg segment reported 8% year-over-year organic growth in net sales to $1.483 billion, with an adjusted operating margin of 34.6% [3]. - The Cardiovascular segment achieved 19% year-over-year organic growth to $2.637 billion, with an adjusted operating margin of 28.9% [4]. Group 4: Growth Drivers - The Cardiovascular segment is expected to continue its growth, driven by the success of devices like POLARx and WATCHMAN FLX Pro, which received FDA approval in 2023 [6]. - The WATCHMAN device is particularly noted for its role in reducing stroke risk, while FARAPULSE devices are recognized as transformative in treating heart rhythm disorders [9]. Group 5: Market Position and Analyst Ratings - Boston Scientific's stock is currently rated as a "Moderate Buy" with a 12-month price target of $85.38, indicating a potential upside of 2.24% [7]. - The highest analyst price target for the stock is $95.00, reflecting positive sentiment among analysts [11].

Boston Scientific (BSX) closed at $82.94 in the latest trading session, marking a -0.14% move from the prior day. This change lagged the S&P 500's 1.07% gain on the day. At the same time, the Dow added 0.31%, and the tech-heavy Nasdaq gained 2.17%.The medical device manufacturer's stock has climbed by 9.4% in the past month, exceeding the Medical sector's gain of 3.34% and the S&P 500's gain of 2.92%.The upcoming earnings release of Boston Scientific will be of great interest to investors. The company is ex ...

UKRAINE - 2021/06/17: In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific (NYSE: BSX) has more than doubled in value since early January 2021 – jumping from levels of $36 then to around $82 now – vs. an increase of about 45% for the S&P 500 over this period. This can primarily be attribute ...

Boston Scientific Corporation (NYSE:BSX) - Key Takeaways from the 2024 Wells Fargo Healthcare Conference Company Overview - **Company**: Boston Scientific Corporation - **Event**: 2024 Wells Fargo Healthcare Conference - **Date**: September 4, 2024 Core Industry Insights - **Industry**: Medical Devices - **Market Growth**: The company is guiding for 13% to 14% organic growth in 2024, reflecting a significant turnaround from a decade ago when it was not growing [3][4] - **Category Leadership**: Boston Scientific has achieved category leadership in several areas, particularly in electrophysiology (EP) and WATCHMAN devices, with a strong growth profile [4][5] Financial Performance - **Organic Growth**: The company reported 14% organic growth in the first half of 2024, with expectations for similar growth in the second half [15][16] - **Operating Margin**: Operating margin performance was reported at 27.2% in Q2, with guidance for an expansion of 50 to 70 basis points in 2024 [18][19] Strategic Initiatives - **M&A Activity**: The company is continuing its tuck-in M&A strategy, with recent acquisitions of Axonics and Silk, while maintaining a strong balance sheet [6][7] - **Regulatory Environment**: Increased scrutiny from the FTC is acknowledged, but the company has always considered regulatory pathways in its M&A calculus [9] Product Development and Pipeline - **FARAPULSE Technology**: FARAPULSE is highlighted as a transformative technology in MedTech, with expectations for significant market penetration [10][28] - **EP Market Potential**: The EP market is expected to grow at over 20%, with WATCHMAN projected to expand from a $1.5 billion market today to $6 billion by 2030 [25][26] - **VC Portfolio**: The company has a robust venture capital portfolio that is expected to contribute to growth over the next 12 to 36 months [12] Geographic Expansion - **China and Japan**: The company has received approval in China and is on track for Japan, both markets estimated at $1 billion each [31][32] - **Market Dynamics**: The company anticipates that Japan may adopt FARAPULSE technology faster than China due to existing market conditions [32] Competitive Landscape - **Market Position**: Boston Scientific is currently the third-largest player in the EP market, with ambitions to become the second [41][42] - **Competitor Awareness**: The company is aware of its competitors, particularly J&J and Abbott, and is focused on enhancing its product portfolio to compete effectively [37][39] Future Outlook - **2025 Guidance**: The company plans to provide updated guidance during the fourth quarter earnings call, with expectations for continued strong performance in cardiology and interventional oncology [20][22] - **Long-term Goals**: The goal is to be the highest-performing MedTech company, with consistent growth and margin improvement [23][81] Additional Highlights - **WATCHMAN and OPTION Trial**: The upcoming OPTION trial results are anticipated to have significant implications for the WATCHMAN device and its market growth potential [49][53] - **AGENT Device**: The AGENT device is showing promise, with expectations for significant growth driven by reimbursement decisions [66][67] - **TAVR Business**: The ACURATE neo2 TAVR device is expected to file for US approval in the first half of 2025, with ongoing momentum in Europe [69][70] Conclusion Boston Scientific is positioned for strong growth in the medical device industry, driven by innovative products, strategic acquisitions, and a focus on operational efficiency. The company is optimistic about its future prospects, particularly in the electrophysiology and cardiology markets, while navigating a complex regulatory environment.

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Core Insights - Boston Scientific has received a CE Mark for the ACURATE Prime Aortic Valve System, enhancing its transcatheter aortic valve replacement (TAVR) technology portfolio [1][2][3] - The new valve system is designed for patients with severe aortic stenosis and offers improved deployment mechanisms and performance in complex cases [2][3] - The global TAVR market is valued at $6.3 billion in 2023, with a projected CAGR of 7.2% by 2030, driven by factors such as the rising prevalence of aortic valve stenosis and the demand for minimally invasive procedures [4] Company Developments - Boston Scientific's second-quarter 2024 financial report indicated strong organic growth in its Cardiology business, particularly in Interventional Cardiology Therapies and Structural Heart Valves [5] - The company plans to launch the ACURATE Prime system in Europe soon, while it remains investigational in the United States [3] - The ACURATE valve platform has been implanted in nearly 80,000 patients globally, showcasing its clinical adoption [3] Market Performance - BSX shares have increased by 46.5% over the past year, outperforming the industry average of 12.7% [7] - Earnings estimates for Boston Scientific's 2024 remain constant at $2.40, with the company consistently beating estimates in the past four quarters [8] - Boston Scientific currently holds a Zacks Rank 2 (Buy), indicating positive market sentiment [9]

MARLBOROUGH, Mass., Aug. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology in the company's structural heart portfolio. The ACURATE Prime valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a ...

It has been about a month since the last earnings report for Boston Scientific (BSX) . Shares have added about 7.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Boston Scientific due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Boston Scientific Q2 Earnings Beat ...